Few clinical decisions in psychiatry feel as weighty as whether to continue an antipsychotic during pregnancy. The pull toward "no medication is safest" is intuitive but not actually supported by the evidence. Untreated psychotic illness during pregnancy carries its own real risks — for the parent, for the developing fetus, and for the postpartum period. The honest answer is that almost every choice in pregnancy psychiatry involves balancing two sets of risks, not choosing between risk and no risk.
Most second-generation antipsychotics have accumulated reasonable safety data in pregnancy, and for many people with schizophrenia the safest path is continuing a working medication under perinatal psychiatric care, because untreated psychosis carries serious risks of its own.
Why this conversation matters
Schizophrenia affects roughly 1% of women, and most are diagnosed before or during their reproductive years. Pregnancy is common. The American College of Obstetricians and Gynecologists (ACOG) explicitly recommends that decisions about psychiatric medication in pregnancy be individualised, with attention to the risks of both the medication and the underlying illness if untreated. Pregnancy alone is not a reason to stop a working antipsychotic.
The risks of untreated psychosis in pregnancy
Relapse during pregnancy in someone with schizophrenia is associated with:
- Poor prenatal care attendance
- Inadequate nutrition
- Substance use as self-medication
- Higher rates of preterm birth and low birth weight
- A markedly elevated risk of postpartum relapse
- Risk of harm to the parent or fetus during acute episodes
Studies summarised by the National Library of Medicine's LactMed and pregnancy resources and by perinatal psychiatry reviews consistently show that the obstetric outcomes of women with untreated serious mental illness are worse than those of women whose illness is treated.
What we know about specific antipsychotics
Most pregnancy data on second-generation antipsychotics come from prospective registries (notably the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics) and large administrative cohorts. The reassuring headline: large studies have not found a clear, consistent signal of major congenital malformations attributable to second-generation antipsychotics as a class.
Olanzapine, quetiapine, risperidone, aripiprazole
These have the most accumulated reproductive safety data. MotherToBaby and similar fact sheets summarise the available cohort data — no clear elevation of malformation risk above the background population rate of roughly 3%. Olanzapine and quetiapine are associated with greater maternal weight gain and higher rates of gestational diabetes; metabolic monitoring is essential.
Clozapine
Used in treatment-resistant schizophrenia. Pregnancy data are smaller but generally reassuring for major malformations. Specific concerns include neonatal sedation, possible floppy infant syndrome, and the need to continue weekly or biweekly absolute neutrophil count monitoring through pregnancy.
Long-acting injectables
Increasingly used in pregnancy when oral adherence is uncertain. Data are still limited but no clear teratogenic signal has emerged for the second-generation injectables.
First-generation antipsychotics
Haloperidol has the longest history of use in pregnancy and has not been clearly linked to malformations at typical doses. High-potency first-generation agents may carry higher risk of neonatal extrapyramidal symptoms.
FDA labelling for third-trimester exposure
In 2011 the FDA added a class warning to all antipsychotic labels noting that third-trimester exposure can cause extrapyramidal and withdrawal symptoms in newborns — tremor, increased or decreased muscle tone, agitation, sleepiness, breathing or feeding difficulties. These are usually self-limited but require neonatal monitoring. The FDA explicitly noted that this risk should not lead to abrupt discontinuation in the third trimester.
Gestational diabetes and weight
Several second-generation antipsychotics — particularly olanzapine, quetiapine, and clozapine — increase the risk of gestational diabetes. Routine ACOG-recommended glucose screening, careful weight monitoring, and nutrition support help. Some teams use earlier glucose tolerance testing in women on these agents.
Folic acid and other prenatal basics
Standard prenatal care matters even more. Folic acid supplementation, prenatal vitamins, abstinence from alcohol and tobacco, and screening for substance use should be in place from the earliest possible point. Women planning pregnancy on any psychiatric medication benefit from preconception counselling — ideally months before trying to conceive. See our preconception counselling guide.
How decisions are typically made
A perinatal psychiatry consultation usually walks through:
- The patient's history of episodes, severity, and response to medications
- The relapse risk if the current medication were stopped or lowered
- The available reproductive safety data for the current and alternative medications
- Pregnancy stage and modifiable risks (metabolic, cardiac)
- The patient's own values and preferences
For many people, the safest plan is to continue a medication that has been keeping them stable rather than switch to one with less reproductive data on the basis of theoretical advantages.
Sudden discontinuation of an antipsychotic — especially in pregnancy — sharply raises relapse risk. Any change should be planned with a psychiatrist, ideally before conception.
Resources for parents and clinicians
- MotherToBaby — free fact sheets and a counsellor helpline
- MGH Center for Women's Mental Health — maintains the National Pregnancy Registry for Atypical Antipsychotics
- NIMH perinatal mental health
- ACOG perinatal mental health resources
The bottom line
Pregnancy on an antipsychotic is not safe in the abstract and not unsafe in the abstract — it depends on the specific medication, the specific person, and the specific risks of their illness. The most dangerous decision is usually the one made alone. With perinatal psychiatric input, careful obstetric care, and a clear plan, most women with schizophrenia can navigate pregnancy and have healthy babies while staying mentally well themselves.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.